Bausch + Lomb stock
BLCONYSEBausch + Lomb Corporation, HealthcareISIN CA0717051076
50Score 50 out of 100, Neutral
Price and trend
79 / 100
Price history
+27% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 26% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 79).
The price is 1.1% below its 52-week high. Largest decline in 5 years: 48% (July 2023 to May 2025).
Chart figures for advanced users
- SMA 50$17.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.83
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)79
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$14.56
- The lowest closing price of the last twelve months.
- Resistance$21.37
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Bausch + Lomb Corporation belongs to the Medical (Instruments & Supplies) industry (Canada) and, with a market value of $7.56B, is number 18 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $5.1B (up 6.5% year on year) and a loss of $360M.
- For fiscal 2026, analysts expect on average revenue of $5.5B (up 7.8%) and adjusted earnings per share of $0.94 (up 87.4%).
Show more
- MEQIRI Score 50 out of 100 (Neutral): rank 379 of 714 in Healthcare, median 53.
- Our model puts fair value at $11.41, with the price 87% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 22.6% a year through 2028 (estimates from 8 analysts).Growth 52
Weaknesses
- Interest barely coveredOperating profit covers interest only 0.3 times.Stability 52
- Above fair valuePrice 87% above the fair value of $11.41.Valuation 25
- Loss-makingLoss of $111M over the last 12 months.Fundamentals 33
Its standout strengths are momentum and technical analysis, while profitability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $8.78 and expensive above $16.30 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $9.39, at 7.8% it would be $14.45.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 8.8% on the twelve months before. Revenue has grown solidly since 2018, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 55%, operating 4%, net −7%. Last 12 months: net −2%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 17 Feb 2027in 97 days
- Last reported
- 28 Oct 2026EPS reported $0.34 (expected $0.21)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 17.9% since 15 Oct 2026.
- Earnings per share
- $0.94+17.9%
- Revenue
- $5.5B+0.1%
- Earnings per share
- $1.19+7.5%
- Revenue
- $5.83B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +15.8%Bausch + Lomb raised its full year 2026 guidance for the third time, now expecting revenue of $5.45 to $5.55 billion and adjusted EBITDA of $1.09 to $1.14 billion, implying a margin of about 20.3%, up from prior expectations.
“At the midpoint, our guidance implies an adjusted EBITDA margin of approximately 20.3%, which is about 130 basis points above our full year 2026 outlook.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $3.49M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Munsch FrederickSale
29 Oct 2026, SVP, Controller and CAO
- Shares
- 112,015
- Price
- $20.48
- Value
- $2.29M
- Munsch FrederickSale
10 Aug 2026, SVP, Controller and CAO
- Shares
- 52,900
- Price
- $16.78
- Value
- $887,662
- Von Eschenbach Andrew C.Sale
7 Aug 2026, Board
- Shares
- 6,059
- Price
- $16.58
- Value
- $100,458
Show 1 more
- Von Eschenbach Andrew C.Sale
6 Aug 2026, Board
- Shares
- 12,500
- Price
- $16.50
- Value
- $206,250
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Bausch + Lomb
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 50
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Cooper CompaniesCOO $11.97B61
- RepligenRGEN $11.03B51
- AvantorAVTR $10.66B53
- AptarGroupATR $9.07B65
- Asahi Intecc7747.T $6.34B83
- Gan & Lee Pharmaceuticals.603087.SS $6.21B56
- TeleflexTFX $6.2B59
- Merit Medical SystemsMMSI $5.28B61
ETFs that hold Bausch + Lomb
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.07% | 0.40% | €807M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 10 Nov 2026, previously Weak
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.